Novartis Patient Support™
A dedicated team for you and your patients
Novartis Patient Support is a comprehensive program that is designed to help your eligible patients start, stay, and save on KISQALI
Your practice and patients will have access to a Novartis Patient Support team committed to providing the support you need, including:
Dedicated assistance with access and reimbursement
Assistance with relevant savings options for your eligible patients
Personalized support for your patients on therapy
Single points of contact for you and your patients
Insurance Support
Our team will help with navigating insurance barriers.
Benefits Verification
Once you’ve enrolled your patients in Novartis Patient Support, our team will conduct a benefits verification to help you better understand your patients’ coverage, including:
Work with your patients’ health plans to understand coverage for KISQALI
9 out of 10 patients have favorable coverage for KISQALI for approved metastatic indications1,*
Inform your practice about additional requirements, such as prior authorization
Identify savings options available to your patients
Prior Authorizations (PAs) and Appeals
Novartis Patient Support can help with PA requests or letters of appeal by providing information to you or your office, including:
Provide best practices and timely updates via phone
Share helpful resources about the PA and appeals process including:
Access and Support Guide, which includes the following:
Checklists and sample letters to help your office prepare and follow up on requests to health plans
Links to available resources to help your patients get started on and afford their KISQALI treatment
ICD-10-CM Flashcard, which includes information on potential codes for KISQALI
*Unrestricted or single-step edit coverage from MMIT data as of June 2024.
Reference: 1. Data on file. Kisqali MMIT data June 2024. Novartis Pharmaceuticals Corp; 2024.
Financial Support
Connecting patients with relevant savings options.
At Novartis Patient Support, we understand that affordability is important to treatment success. That’s why we offer a range of savings options to help your patients access treatment regardless of their ability to pay.
Co-Pay Plus
We help make treatment more affordable for your eligible patients through our Co-Pay Plus offer.
To sign up for the $0 Co-Pay Plus offer:
The Bridge Program
Up to 5 free treatment cycles of KISQALI through the Bridge Program† while health plan coverage is pursued.
Once patients enroll in Novartis Patient Support, we automatically identify if they are eligible for the Bridge Program based on the results of the benefits verification.
Patients can receive up to 5 free treatment cycles of KISQALI.
Privately insured patients waiting for their coverage to take effect for KISQALI and/or FEMARA® (including generic letrozole) may be eligible for an additional supply of KISQALI that could continue for up to 5 treatment cycles.
Once we’ve determined your patient’s coverage status, we’ll help transition them to any appropriate financial support offering.
To enroll your eligible patient in this patient support service, submit a completed Novartis Patient Support Start Form or reach out to your Dedicated Novartis Associate Director, Access & Reimbursement (ADAR).
Free Trial Offer
With our Free Trial Offer,‡ patients can start on KISQALI today at no cost.
How does the Free Trial Offer‡ work?
- Your patients are eligible to receive a 1-treatment-cycle supply of KISQALI and/or FEMARA (including generic letrozole) at no cost
- No purchase required of KISQALI and/or FEMARA (including generic letrozole)
- This offer is available for patients with a valid prescription for KISQALI and/or FEMARA (including generic letrozole), including patients who have not been prescribed KISQALI or another Novartis product
‡No purchase required. This free trial is not health insurance. Void where prohibited by law. Product dispensed pursuant to terms and conditions of offer. Valid only in the US and Puerto Rico. For Massachusetts residents, offer is valid for one of the following: the KISQALI FEMARA Co-Pack or KISQALI and/or generic letrozole. Claims shall not be submitted to any public or private third-party payer or any federal or state health care program for reimbursement. Offer not valid if reproduced or submitted to any other payer. It is illegal for any person to sell, purchase or trade, or offer to sell, purchase or trade, or to counterfeit, this offer. Prescriber ID# required on prescription. This is the property of Novartis Pharmaceuticals Corporation and must be returned upon request. Novartis Pharmaceuticals Corporation reserves the right to rescind, revoke, or amend this offer without notice.
The Novartis Patient Assistance Foundation, Inc (NPAF)
What if I don't have insurance?
Novartis Patient Assistance Foundation, Inc. (NPAF), an independent 501(c)(3) non-profit organization, provides Novartis medications free of cost to eligible patients who have limited or no prescription insurance coverage and cannot afford the cost of their medication.
To be eligible, you must:
Reside in the United States or a US Territory
Be treated by a licensed US health care provider on an outpatient basis
Meet income and insurance guidelines
Questions?
Visit PAP.Novartis.com or call NPAF at 1-800-277-2254 to learn more about eligibility and how to apply
Get your patients started by downloading the Start Form.
Clinical Testing and Support
We provide workflow support and options for testing, including:
Clinical educators to answer your office with questions about testing needs for KISQALI
ECG device program so your patients can receive their ECG assessment in seconds in your office or at home
There is no direct cost to you or your patients for participating in this program.
Download the Start Form to fill out applicable information for ECG testing support.
Limitations apply. KISQALI ECG Device Monitoring Program is only permitted to be used for monitoring or evaluating a patient for the current or potential administration of ribociclib. The equipment or services are not permitted to be used for any purpose outside of the scope of the program. You must not bill any entity or person for any equipment or services relating to the provision or interpretation of the ECG. In the event that you fail to abide by the rules of the KISQALI ECG Device Monitoring Program, your participation in the program may be terminated or modified at any time without prior notice, and you may be subject to additional remedies. Additional terms and conditions apply.
Sunshine Act costs may apply.
To learn more, contact your dedicated Novartis Patient Support Team at 1-866-433-8000, Monday-Friday, 8:00 AM - 8:00 PM ET, excluding holidays.
Ongoing Support
Novartis Patient Support provides patients with ongoing help to stay on track with their KISQALI treatment plan, including:
A dedicated Novartis Patient Support Team member to answer their questions at every step
Information on financial support options
Help navigating health care changes
Tips for setting up a routine that can help patients stay on track with their medication dosing
Educational resources about KISQALI and living with breast cancer
A brochure that can help them find answers to many of their questions
A list of independent support organizations that can offer services to help with treatment
Tips for talking to their health care provider
Email communications tailored to their treatment journey
A choice of texts and calls, including tips to keep them on track
To learn more, contact your dedicated Novartis Patient Support Team at 1-866-433-8000, Monday-Friday, 8:00 AM - 8:00 PM ET, excluding holidays.
Getting Patients Started With Novartis Patient Support
Resources
Novartis Patient Support has helpful resources to support your patient’s treatment journey.
Start Form
Start Form Guide
ICD-10-CM Flashcard
KISQALI Access Support Guide
Formulary Change Flashcard
KISQALI ECG Program Brochure
KISQALI Financial Assistance Slim Jim
Questions?
For more information on available resources, call Novartis Patient Support at 1-866-433-8000, Monday-Friday, 8:00 AM - 8:00 PM ET, excluding holidays.